Lactoferrin

VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024

Retrieved on: 
Wednesday, March 27, 2024
SAN, Research, Allergy, Interview, Telecanthus, FDA, Immunoglobulin E, Lactoferrin, Pharmaceutical industry

SAN DIEGO, CA, March 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire –AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, today released a fireside chat interview conducted with its CEO John Huemoeller II and Tony Noto at the 2024 Benzinga Virtual Healthcare Summit. During the presentation, Mr. Huemoeller shares insights into the Company’s work with its two FDA-cleared ophthalmological diagnostic assays currently being marketed to clinicians throughout the country as well as research being conducted in its Parkinson’s diagnostic program.

Key Points: 
  • SAN DIEGO, CA, March 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – AXIM Biotechnologies, Inc .
  • ( OTCQB: AXIM ) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, today released a fireside chat interview conducted with its CEO John Huemoeller II and Tony Noto at the 2024 Benzinga Virtual Healthcare Summit .
  • The presentation can be viewed here: https://aximbiotech.com/presentations/
    “We’re in the diagnostic solutions segment using teardrops and have mastered a couple of tests already, Lactoferrin which is for dry eye disease, and IgE which is for allergies,” said John Huemoeller II, CEO of AXIM Biotechnologies during the presentation.
  • So now that we've been able to master that, it's allowed us to move into other places, such as Parkinson's,” added Huemoeller.

Weston A. Price Foundation Proposes Deeper Look Into the Cause of TB

Retrieved on: 
Friday, March 22, 2024
Chelation, Crimean War, Industrial Age, Periodic breathing, Health, Meat, Siderosis, Cough, Natural gas, TIME, Lactoferrin, Coal, Mycobacterium tuberculosis, Disease, Tuberculosis, Incidence, Anglo-French Wars, Iron, Research, Mystery, Weston A. Price Foundation, Stainless steel, Death, Human, Bacillus, IRON, Atmosphere, Vaccination, Industrialisation, Contagious disease, TB, Power, Aluminium, Multimedia, Blood

DALLAS, March 22, 2024 /PRNewswire/ -- World TB Day, March 24, commemorates the date in 1882 when Dr. Robert Koch announced his discovery of Mycobacterium tuberculosis, the bacillus believed to cause tuberculosis (TB). Koch argued that TB is a contagious disease, spreading from one person to the next through the air. Based on the notion that TB is caused by a contagious bacterium, conventional treatment for TB involves vaccination and administration of multiple antibiotics over a long period. New information requires the scientific community to reexamine the reigning theories about tuberculosis.

Key Points: 
  • DALLAS, March 22, 2024 /PRNewswire/ -- World TB Day, March 24, commemorates the date in 1882 when Dr. Robert Koch announced his discovery of Mycobacterium tuberculosis , the bacillus believed to cause tuberculosis (TB).
  • Koch argued that TB is a contagious disease, spreading from one person to the next through the air.
  • "We propose looking elsewhere for the cause of TB," says Sally Fallon Morel of the Weston A.
  • "We propose looking elsewhere for the cause of this terrible illness," says Sally Fallon Morell, president of the Weston A.

TurtleTree Secures First Vegan Certification for Precision Fermentation Dairy Industry

Retrieved on: 
Wednesday, February 14, 2024
Food, LF, Animal, Lactoferrin, Fermentation, Certification, Vegan Awareness Foundation, Entrepreneurship

WOODLAND, Calif., Feb. 14, 2024 /PRNewswire/ -- TurtleTree, a pioneer in sustainable nutrition, and Vegan Action, the most recognized vegan certification provider in the U.S. today announced the official vegan certification of TurtleTree's animal-free sustainable lactoferrin, LF+. This milestone establishes TurtleTree as the first precision fermentation dairy company globally to obtain vegan certification, and the first ever to receive the Certified Vegan logo in the 24 years it's been administered. In taking this step, TurtleTree has solidified its unwavering commitment to animal welfare as well as meeting the evolving demands of conscious consumers.

Key Points: 
  • The leading and most trusted provider of vegan certification in North America gives TurtleTree's sustainable lactoferrin, LF+,  the stamp of approval, setting new industry standards
    WOODLAND, Calif., Feb. 14, 2024 /PRNewswire/ -- TurtleTree , a pioneer in sustainable nutrition, and Vegan Action , the most recognized vegan certification provider in the U.S. today announced the official vegan certification of TurtleTree's animal-free sustainable lactoferrin, LF+ .
  • This milestone establishes TurtleTree as the first precision fermentation dairy company globally to obtain vegan certification, and the first ever to receive the Certified Vegan logo in the 24 years it's been administered.
  • This is a hot-button issue and potentially the reason most precision fermentation companies haven't pursued official certification, despite stating they are vegan and animal-free.
  • Turtletree has taken a pioneering step by securing vegan certification for its bioidentical dairy protein, LF+, confirming strict adherence to the highest ethical standards.

Yili Group Celebrates Dynamic Global Relationships at the Top Partners Conference 2024

Retrieved on: 
Wednesday, December 27, 2023
Forward, Conference, Milk, Atom, Probiotic, Yili Group, HMO, Lactoferrin, Unit, Face, Growth, Small Business Saturday, Dietary supplement

SANYA, China, Dec. 27, 2023 /PRNewswire/ -- Between December 6 and 20, Yili Group and its Thai and Indonesian subsidiaries, respectively, brought together global partners for their Top Partners Conference 2024, themed "Grow with Innovation, Forward in Unity."

Key Points: 
  • SANYA, China, Dec. 27, 2023 /PRNewswire/ -- Between December 6 and 20, Yili Group and its Thai and Indonesian subsidiaries, respectively, brought together global partners for their Top Partners Conference 2024, themed "Grow with Innovation, Forward in Unity."
  • Yili's international business has experienced sustained and rapid growth, driven by the expansion of its strategic global network.
  • At the Top Partners Conference, Yili showered global partners with accolades, unveiling over a thousand awards across diverse categories, including team management, channel development, and outlet retailing.
  • This commitment to shared success has resulted in a robust global network of over 2,000 partners.

Yili Group Celebrates Dynamic Global Relationships at the Top Partners Conference 2024

Retrieved on: 
Wednesday, December 27, 2023
Forward, Conference, Milk, Atom, Probiotic, Yili Group, HMO, Lactoferrin, Unit, Face, Growth, Small Business Saturday, Dietary supplement

SANYA, China, Dec. 27, 2023 /PRNewswire/ -- Between December 6 and 20, Yili Group and its Thai and Indonesian subsidiaries, respectively, brought together global partners for their Top Partners Conference 2024, themed "Grow with Innovation, Forward in Unity."

Key Points: 
  • SANYA, China, Dec. 27, 2023 /PRNewswire/ -- Between December 6 and 20, Yili Group and its Thai and Indonesian subsidiaries, respectively, brought together global partners for their Top Partners Conference 2024, themed "Grow with Innovation, Forward in Unity."
  • Yili's international business has experienced sustained and rapid growth, driven by the expansion of its strategic global network.
  • At the Top Partners Conference, Yili showered global partners with accolades, unveiling over a thousand awards across diverse categories, including team management, channel development, and outlet retailing.
  • This commitment to shared success has resulted in a robust global network of over 2,000 partners.

AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease

Retrieved on: 
Tuesday, September 12, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Alpha-synuclein, PD, Centrifugation, Celsius, Neurodegenerative disease, The Michael J. Fox Foundation, Tears, II, Organization, Bicinchoninic acid assay, Parkinson's disease, Synuclein, Patient, Freezing, Lactoferrin, Diagnosis, III, Alzheimer's disease, Medical imaging, Palladium

Fox Foundation shows that the presence of abnormal alpha-synuclein was detected in an astonishing 93% of people with Parkinson’s who participated in the study.

Key Points: 
  • Fox Foundation shows that the presence of abnormal alpha-synuclein was detected in an astonishing 93% of people with Parkinson’s who participated in the study.
  • These findings suggest a crucial role for α-synuclein in therapeutic development, both in identifying pathologically defined subgroups of people with Parkinson's disease and establishing biomarker-defined at-risk cohorts.
  • Total tear protein content is first quantified using a bicinchoninic acid assay followed by alpha-Synuclein using a bulky plate reader.
  • AXIM is already marketing a lactoferrin assay, which may be used in conjunction with the newly developed novel Synuclein test.

ByHeart, the Only New U.S.-Made Brand to Rewrite the Infant Formula Recipe from Scratch, Announces Retail Debut Nationwide, to be Followed by Highly Anticipated DTC Relaunch

Retrieved on: 
Monday, August 21, 2023
Target, DTC, Entrepreneurship, Infant, Food, Palm oil, Target Corporation, Lactoferrin, Breast milk, Dietary supplement

Following on its successful DTC launch in 2022, ByHeart's groundbreaking infant formula will be available in brick-and-mortar for the first time and on Target.com.

Key Points: 
  • Following on its successful DTC launch in 2022, ByHeart's groundbreaking infant formula will be available in brick-and-mortar for the first time and on Target.com.
  • The company also announced it will relaunch its product direct-to-consumer at ByHeart.com later this year.
  • The revolutionary recipe is the only U.S.-made infant formula to include organic, grass-fed whole milk and the only clinically proven, easy to digest formula with no corn syrup, maltodextrin, soy, or palm oil.
  • "We believe infant formula is the most important food for the most important people and we treat it that way from start to finish," said Mia Funt, President and Co-Founder of ByHeart.

AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test

Retrieved on: 
Tuesday, August 1, 2023
Software, Research, Pharmaceutical, Optical, Oncology, Medical Devices, Technology, Health Technology, Science, COVID-19, Biotechnology, Health, Infection, Patent, University, University of Houston, Urine, ECS, SAR, Serum, QSOX1, Survival, Telecanthus, Tears, Cancer, EIS, SARS, Bladder cancer, Brain, Attention, COVID, Provisional application, IP, Biomarker, Person, Lacritin, Plasma, Ebola virus disease treatment research, Eye, Diagnosis, Immunoglobulin E, FDA, A-DNA, Virus, Tearing, Fentanyl, Treatment, SARS-CoV-2, Vaccine, Natural rubber, Medical imaging, Lactoferrin, Blepharitis

The first patent application recently allowed relates to COVID and other neutralizing antibody (Nab) testing and treatment.

Key Points: 
  • The first patent application recently allowed relates to COVID and other neutralizing antibody (Nab) testing and treatment.
  • The allowance confirms that AXIM was a pioneer in developing a rapid point of care Nab test and its novelty.
  • Additionally, the company was notified by the USPTO of a second patent allowance for systems and methods for rapid diagnostic for various cancers.
  • 1 Utility Patent Application
    The invention relates to a Rapid Point of Care test for Human Monomeric Lacritin.

Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform

Retrieved on: 
Tuesday, July 25, 2023
Health, Surgery, Other Science, General Health, Research, Science, Optical, DED, Ophthalmic, OTCQB, OSD, Biomarker, Lactoferrin, Telecanthus, MD, Patient, Allergic conjunctivitis, Diagnosis, Tear, Immunoglobulin E, Pharmaceutical industry, Medical imaging

T-POC TOTAL IgE Immunoassay Kit is a new quantitative point-of-care test used in the diagnosis and management of patients suffering from ocular surface disease (OSD).

Key Points: 
  • T-POC TOTAL IgE Immunoassay Kit is a new quantitative point-of-care test used in the diagnosis and management of patients suffering from ocular surface disease (OSD).
  • While today marks a milestone for the company with this initial shipment of its novel testing platform, it represents only the first phase that will focus on TOTAL IgE.
  • Rob Sambursky, MD, President of Verséa Ophthalmics stated: “Verséa Ophthalmics is proud to bring the innovative T-POC Quantitative Testing Platform to eye care professionals to aid them in appropriately diagnosing, managing, and treating their patients with ocular surface disease.
  • For more information on the T-POC Quantitative Testing Platform, please visit www.versea.com/ophthalmics .

Study Reveals Prolacta's 100% Human Milk-Based Nutritional Fortifiers Significantly Increase Bioactive Proteins and Antioxidant Activity in Human Milk Samples, Outperforming Cow Milk-Based Fortifier

Retrieved on: 
Monday, June 12, 2023
Hospice and palliative medicine, Breastfeeding Support for Indian Mothers, University, Immunity, Literature review, MBA, DHM, Milk, MOM, MD, Lactoferrin, University of Limerick, Dairy, Growth

DUARTE, Calif., June 12, 2023 /PRNewswire/ -- Prolacta Bioscience, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, today announced that Breastfeeding Medicine has published an independent study demonstrating Prolacta's human milk-based fortifiers (HMBF) reinstate and significantly boost bioactive proteins when added to mother's own milk (MOM) and donor human milk (DHM).1 The naturally occurring bioactive components in human milk are thought to support infants' immunity, development, growth, and long-term health.2

Key Points: 
  • It was authored by Professor Roy K. Philip, MD, MBA, and colleagues of the University of Limerick School of Medicine, and Bernal Institute, University of Limerick, Ireland.
  • "Pasteurized donor human milk showed significantly low bioactive properties in comparison to fresh and frozen MOM; however, the addition of HMBF reinstated and further enhanced bioactivity to partially offset the effects of pasteurization.
  • "1
    The study found milk samples fortified with Prolacta's HMBF contained higher protein, fat, and total solids (p
  • "3-16
    On June 27, Professor Philip will present his study findings in a webinar titled Exclusive Human Milk Diet (EHMD) for Extremely Premature Infants: a Fortification Strategy to Enhance Bioactivity.